Stephen D. Wiviott

Q: What Schools Are Affiliated With Stephen D. Wiviott

Stephen D. Wiviott is affiliated with the following schools: University of Oklahoma Health Sciences Center, University of Colorado Denver, United States Military Academy, Massachusetts General Hospital, Kyoto University, Duke University, University of Texas Southwestern Medical Center, University of Alabama at Birmingham

Stephen D. Wiviott's AcademicInfluence.com Rankings

Stephen D. Wiviott

Philosophy

#6503

World Rank

#9548

Historical Rank

Logic

#3657

World Rank

#4850

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Stephen D. Wiviott's Degrees

Doctorate Medicine Harvard University

Why Is Stephen D. Wiviott Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stephen D. Wiviott's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prasugrel versus clopidogrel in patients with acute coronary syndromes. (2007) (6103)
Edoxaban versus warfarin in patients with atrial fibrillation. (2013) (3988)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) (3562)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium (2011) (3111)
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. (2013) (3012)
Cytochrome p-450 polymorphisms and response to clopidogrel. (2009) (2405)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2019) (2285)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. (2015) (1787)
Rivaroxaban in patients with a recent acute coronary syndrome. (2012) (1745)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) (1687)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. (2014) (1564)
Long-term use of ticagrelor in patients with prior myocardial infarction. (2015) (1399)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. (2004) (1346)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial (2009) (1082)
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. (2015) (1081)
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. (2010) (1061)
Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial (2007) (905)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. (2016) (854)
Vorapaxar in the secondary prevention of atherothrombotic events. (2012) (839)
Coronary CT angiography versus standard evaluation in acute chest pain. (2012) (788)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (2008) (744)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials (2009) (741)
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis (2010) (601)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. (2007) (569)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes (2009) (521)
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial (2008) (467)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. (2019) (424)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials (2019) (415)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. (2017) (403)
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial (2005) (398)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. (2019) (386)
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. (2005) (341)
Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Report From the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network R (2010) (340)
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). (2006) (332)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. (2008) (327)
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial (2006) (302)
Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. (2003) (297)
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. (2014) (288)
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. (2018) (285)
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. (2009) (252)
Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. (2009) (251)
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (2018) (248)
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. (2015) (240)
Clopidogrel resistance: a new chapter in a fast-moving story. (2004) (205)
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology (2019) (202)
Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18) Substudy (2004) (200)
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. (2019) (192)
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (2009) (190)
Cytochrome P 450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic , Pharmacodynamic , and Clinical Outcomes (2009) (183)
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. (2016) (179)
Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) (2011) (172)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER (2018) (171)
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients (2018) (168)
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. (2007) (166)
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent (2010) (162)
Use of Emergency Medical Service Transport Among Patients With ST-Segment–Elevation Myocardial Infarction: Findings From the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry–Get With the Guidelines (2011) (161)
Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin–Acute Coronary Syndromes Trial (2011) (147)
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial (2008) (146)
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. (2004) (145)
Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI (2010) (145)
Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? (2006) (138)
Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study (2017) (136)
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020) (127)
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis (2018) (124)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial (2017) (124)
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004) (123)
Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin–Coronary Artery Disease Trial (2011) (123)
Short-Term Outcomes of Acute Myocardial Infarction in Patients With Acute Kidney Injury: A Report From the National Cardiovascular Data Registry (2012) (122)
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. (2019) (122)
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial (2013) (118)
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial (2018) (112)
High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. (2015) (111)
ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial (2011) (110)
A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 (2006) (110)
Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. (2004) (106)
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis (2009) (105)
DECLARE‐TIMI 58: Participants’ baseline characteristics (2018) (101)
Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry (2014) (91)
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. (2019) (91)
Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. (2011) (90)
The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. (2016) (88)
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2017) (87)
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. (2019) (84)
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). (2007) (82)
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. (2019) (80)
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. (2007) (80)
Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. (2007) (76)
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38 (2009) (76)
Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). (2010) (76)
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. (2016) (75)
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. (2013) (70)
Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. (2011) (69)
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. (2006) (69)
Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) su (2010) (68)
Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. (2006) (68)
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study (2019) (62)
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. (2011) (61)
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial (2016) (60)
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes (2015) (57)
Comparison of the Prognostic Value of Peak Creatine Kinase‐MB and Troponin Levels Among Patients With Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines (2012) (57)
Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. (2006) (55)
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. (2019) (55)
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. (2016) (55)
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. (2004) (53)
Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (2014) (52)
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). (2011) (52)
Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. (2004) (51)
Clopidogrel response variability, resistance, or both? (2006) (49)
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. (2017) (47)
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In (2014) (47)
Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. (2019) (47)
Risk of Heart Failure Complication During Hospitalization for Acute Myocardial Infarction in a Contemporary Population: Insights From the National Cardiovascular Data ACTION Registry (2012) (46)
Clinical trial participation after myocardial infarction in a national cardiovascular data registry. (2014) (46)
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel (2011) (46)
Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. (2012) (46)
Sex Differences in the Effectiveness of Early Coronary Computed Tomographic Angiography Compared With Standard Emergency Department Evaluation for Acute Chest Pain: The Rule-Out Myocardial Infarction With Computer-Assisted Tomography (ROMICAT)-II Trial (2013) (45)
Causes of late mortality with dual antiplatelet therapy after coronary stents. (2015) (43)
Race and Sex Differences in Management and Outcomes of Patients After ST‐Elevation and Non–ST‐Elevation Myocardial Infarct: Results From the NCDR (2016) (42)
Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials (2014) (42)
Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. (2012) (41)
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). (2013) (40)
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). (2013) (39)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. (2019) (38)
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). (2008) (38)
Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement. (1992) (37)
Comparison of outcomes in patients aged <75, 75 to 84, and ≥ 85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG). (2010) (37)
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16 (2008) (36)
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus (2020) (36)
Optimal medical therapy with or without PCI for stable coronary artery disease (2007) (36)
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials (2022) (35)
Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) (35)
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. (2014) (35)
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). (2009) (34)
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit (2014) (33)
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myo (2009) (33)
Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China (2020) (33)
Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. (2009) (32)
New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. (2014) (32)
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial (2014) (31)
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial (2019) (31)
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58 (2020) (31)
DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL (2019) (31)
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58 (2020) (30)
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease (2022) (29)
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes (2015) (29)
Unstable angina and non-ST-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care. (2004) (28)
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials (2018) (27)
The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy (2006) (27)
Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban) (2017) (26)
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. (2015) (26)
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58 (2020) (25)
No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. (2011) (25)
Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results From the National Cardiovascular Data Registry (NCDR) (2014) (24)
Relation Between Time of Symptom Onset of ST‐Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry (2013) (24)
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. (2007) (24)
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 (2021) (24)
The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. (2018) (24)
Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. (2015) (24)
Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. (2010) (23)
Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the national registry of myocardial infarction: A simple risk index predicts mortality in both ST and non-ST elevation myocardial infarction (2003) (23)
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. (2016) (23)
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. (2012) (23)
Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. (2013) (23)
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. (2020) (22)
Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis (2009) (22)
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. (2012) (22)
RACE AND SEX DIFFERENCES IN MANAGEMENT AND OUTCOMES OF PATIENTS AFTER ST-ELEVATION AND NON-ST-ELEVATION MYOCARDIAL INFARCT: RESULTS FROM THE NCDR® (2012) (22)
Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). (2009) (21)
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study (2020) (21)
Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction (2012) (20)
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial (2015) (20)
Clinical Features, Use of Evidence‐Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non–ST‐Elevation Acute Coronary Syndrome (2014) (19)
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. (2020) (19)
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 (2021) (18)
Influence of presenting electrocardiographic findings on the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction. (2014) (18)
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF–TIMI 48 (2018) (18)
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel (2016) (18)
Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program (2012) (17)
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. (2020) (17)
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. (2021) (16)
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). (2007) (16)
Update on lipid-lowering therapy and LDL-cholesterol targets (2006) (15)
Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non–ST-Segment–Elevation Myocardial Infarction Patients on Home Warfarin Therapy: Insights From the National Cardiovascular Data Registry (2012) (15)
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. (2019) (15)
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. (2008) (15)
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial (2020) (15)
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 (2015) (14)
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (2021) (14)
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA‐TIMI 61) trial (2018) (14)
Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition (2013) (14)
Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long‐Term Follow‐Up After Acute Coronary Syndromes (2017) (13)
Comparison of Outcomes in Patients Aged 85 Years With ST-Elevation Myocardial Infarction (from the ACTION Registry-GWTG) (2010) (12)
Mortality in the TRITON trial: update from the FDA prasugrel action package. (2010) (12)
244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial (2019) (12)
Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens (2009) (11)
Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. (2013) (11)
Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non–ST-Segment–Elevation Myocardial Infarction (2012) (11)
Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. (2014) (10)
Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). (2011) (10)
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. (2007) (9)
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization (2017) (9)
Abstract 1515: Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. Results From the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. (2007) (9)
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus (2021) (9)
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. (2006) (9)
Final Report of the OSLER-1 Study: Long-Term Evolocumab for the Treatment of Hypercholesterolemia (2018) (9)
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT (2022) (9)
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials (2021) (9)
Therapeutic goals for effective platelet inhibition: a consensus document. (2006) (9)
Acute Stress Cardiomyopathy and Reversible Left Ventricular Dysfunction (8)
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis (2022) (7)
New antiplatelet therapies for acute coronary syndromes (2007) (7)
Unstable angina and non-ST-segment elevation myocardial infarction: part II. Coronary revascularization, hospital discharge, and post-hospital care. (2004) (7)
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease (2021) (7)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. (2022) (7)
TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. (2007) (7)
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. (2010) (7)
Use of systemic bivalirudin with catheter‐directed thrombolysis in a patient with heparin‐induced thrombocytopenia: A case report (2018) (7)
Coronary Heart Disease Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non – ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease A Report From the National Cardiovascular Data Acute Coronary Treatment and Interve (2010) (7)
Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention (2020) (7)
Abstract 1999: Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndrome Presenting with Isolated Anterior ST-Segment Depressions (2008) (6)
Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. (2011) (6)
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? (2008) (6)
Abstract 3994: Pharmacodynamic Assessment of Platelet Inhibition by Prasugrel versus Clopidogrel in the TRITON-TIMI 38 Trial (2008) (6)
Clinical Implications and Correlates of Q Waves in Patients With ST‐Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY‐TIMI 28 Trial (2014) (6)
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes (2021) (6)
Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic , Pharmacodynamic , and Clinical Outcomes (2009) (5)
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. (2022) (5)
Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial (2017) (5)
Abstract 19694: Reduction in Non-hemorrhagic Stroke With Ezetimibe/Simvastatin Compared With Simvastatin Alone in the IMPROVE-IT Trial (2015) (5)
192Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58 (2019) (5)
Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction (2011) (5)
Prasugrel Versus Ticagrelor: Uncertainty Remains (2016) (5)
DISCHARGE ASPIRIN DOSE AND CLINICAL OUTCOMES IN PATIENTS WITH ACS: AN ANALYSIS FROM THE TRITON-TIMI 38 STUDY (2012) (5)
ABCB1 GENETIC VARIANTS, PHARMACODYNAMIC RESPONSE, AND CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH CLOPIDOGREL AND PRASUGREL (2010) (5)
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022) (5)
Patterns of Long‐term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI‐38 Coronary Stent Registry (2014) (4)
Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome. (2018) (4)
Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes Insights From the TAO Trial (2018) (4)
Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. (2021) (4)
Classification of Deaths in Cardiovascular Outcomes Trials: Known Unknowns and Unknown Unknowns (2019) (4)
Intensive antiplatelet therapy for reduction of ischaemic events – Authors' reply (2008) (4)
Coronary Treatment and Intervention Outcomes Network Registry With Chronic Kidney Disease : A Report From the National Cardiovascular Data Acute ST-Segment Elevation Myocardial Infarction in Patients − Myocardial Infarction and Non Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment (2010) (4)
ILLUMINATE sheds more light. (2011) (4)
Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain. (2016) (4)
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. (2013) (4)
Abstract 1439: Cytochrome P450 Genetic Variants Predict Cardiovascular Outcomes following Treatment with Clopidogrel but not with Prasugrel (2008) (4)
Clinical applications of antiplatelet therapy. (2006) (4)
SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply (2019) (4)
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo (2020) (4)
Combination therapy with clopidogrel and proton-pump inhibitors – Authors' reply (2010) (4)
Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38 (2008) (4)
TIMING AND CLINICAL SETTING OF CARDIOVASCULAR DEATH OR MYOCARDIAL INFARCTION FOLLOWING PCI FOR ACS – OBSERVATIONS FROM THE TRITON-TIMI 38 TRIAL (2012) (4)
OUTCOMES AND READMISSION RATE WITHIN 30 DAYS AND 6 MONTHS AFTER ACUTE MYOCARDIAL INFARCTION IN CHINA: DATA FROM THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY (2016) (3)
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. (2020) (3)
UTILITY OF CORONARY ARTERY CALCIUM SCANNING IN EMERGENCY DEPARTMENT EVALUATION FOR ACUTE CHEST PAIN: THE ROMICAT II TRIAL (2013) (3)
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial (2022) (3)
Prasugrel STEMI subgroup analysis – Authors' reply (2009) (3)
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL (2020) (3)
Abstract 16714: Characterization of Types and Sizes of Myocardial Infarction Reduced With Evolocumab in FOURIER (2017) (3)
RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL (2013) (3)
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE (2023) (2)
Abstract 1710: Platelet Function in Diabetes Mellitus: Observations From the PRINCIPLE-TIMI 44 Trial (2009) (2)
THE EFFECTS OF ADDING THE CETP INHIBITOR ANACETRAPIB TO STATIN ON URGENT AND ROUTINE REVASCULARIZATION: RESULTS FROM THE HPS 3/TIMI 55-REVEAL TRIAL (2018) (2)
Abstract 985: The Influence of the Arterial Access Site and its Management on Bleeding Events in Acute Coronary Syndromes in TRITON - TIMI 38 (2008) (2)
Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). (2018) (2)
Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". (2020) (2)
Effect of Darapladib onMajor Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial (2014) (2)
Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. (2020) (2)
Abstract 17950: High-Dose Edoxaban Regimen versus Warfarin in Patients With Atrial Fibrillation and Established Coronary Artery Disease: Insights From the ENGAGE AF-TIMI 48 Trial (2017) (2)
and Intervention Outcomes Network) Registry (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment Acute ST-Segment Elevation Myocardial Infarction: Data From the NCDR Utilization and Impact of Pre-Hospital Electrocardiograms for Patients With (2011) (2)
Abstract 18928: Vorapaxar Reduces Coronary Stent Thrombosis: Results From the TRA2P-TIMI 50 Trial (2013) (2)
Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58 (2019) (2)
Abstract 9309: Benefit of Prasugrel in ST-Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: Insight from the TRITON-TIMI 38 Study (2011) (2)
PERFORMANCE OF TWO SENSITIVE TROPONIN I ASSAYS FOR THE EVALUATION OF SUSPECTED ACS: RESULTS FROM THE MULTICENTER RULE OUT MYOCARDIAL INFARCTION USING COMPUTER ASSISTED TOMOGRAPHY (ROMICAT) II BIOMARKER SUB-STUDY (2013) (2)
Coronary Stent Thrombosis With Vorapaxar Versus Placebo (2015) (2)
Antiplatelet Therapy In Ischemic Heart Disease (2008) (2)
Novel antithrombotic agents 2 Clinical evidence for oral antiplatelet therapy in acute coronary syndromes (2015) (2)
Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. (2021) (2)
Abstract 17455: Pharmacodynamic Response to Clopidogrel in Men versus Women: Insights from the PRINCIPLE-TIMI 44 Trial (2012) (2)
THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS (2013) (2)
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. (2023) (1)
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. (2020) (1)
Questioning the safety and benefits of evolocumab - Authors' reply. (2018) (1)
CHALLENGES IN THE TREATMENT OF NSTEMI PATIENTS AT HIGH RISK FOR BOTH ISCHEMIC AND BLEEDING EVENTS: INSIGHTS FROM THE ACTION REGISTRY-GWTG (2011) (1)
Abstract 15134: Comparison of Events Across Definitions of Major Bleeding in the Engage AF-TIMI 48 Trial (2017) (1)
MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58 (2021) (1)
Abstract 3075: Evaluation of Monocyte Chemoattractant Protein 1 as a Prognostic Marker in the A to Z Trial (2006) (1)
1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58 (2020) (1)
Comprar Antiplatelet Therapy In Ischemic Heart Disease | Julie Barlow | 9781405176262 | Wiley (2009) (1)
Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58 (2020) (1)
When stable becomes unstable: the perils of impersonal medicine. (2011) (1)
On-clopidogrel platelet reactivity: a target in sight? (2011) (1)
Another step on the road to tailored antiplatelet therapy. (2010) (1)
Chapter 10 – Non ST-Elevation Acute Coronary Syndromes (2007) (1)
Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58 (2020) (1)
Gender differences in cardiac biomarkers in patients with unstable angina and non-ST elevation myocardial infarction in TACTICS-TIMI 18 (2003) (1)
Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". (2019) (1)
Evaluation of Mitral Valve Regurgitation : Implications for Percutaneous Mitral Valve Repair (1)
Abstract 11255: PON1 Q192R (rs662) Genetic Variant and Response to Clopidogrel and Prasugrel (2011) (1)
Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. (2021) (1)
Global risk assessment for lipid therapy to prevent coronary heart disease (2000) (1)
Abstract 13975: Association of In-Hospital Acute Kidney Injury With Long-term Outcomes in Survivors of Acute Myocardial Infarction: Insight From the NCDR (2015) (1)
Abstract 5581: Cardiovascular Outcomes of Women and Men with Acute Coronary Syndromes and Angiographically Confirmed Epicardial Coronary Artery Disease in TRITON-TIMI 38 (2008) (1)
COMPARISON OF THE PROGNOSTIC VALUE OF PEAK CK-MB AND TROPONIN LEVELS AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (2010) (1)
ACUTE MYOCARDIAL INFARCTION CARE ACROSS THREE LEVELS OF HOSPITALS IN CHINA: A REPORT FROM THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY (2015) (1)
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. (2022) (1)
173: NON-INVASIVE MEASURE OF TISSUE PERFUSION, SMO2, COMPARED WITH STANDARD INVASIVE ASSESSMENTS OF SHOCK (2014) (1)
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. (2020) (1)
Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial (2019) (1)
P5106Prevalence, clinical characteristics and outcomes of procedural complications of percutaneous coronary intervention in non ST-elevation myocardial infarction: insights from the TAO trial (2018) (1)
The Pleiotropic Effects of Statins : Fact or Fantasy ? (1)
Abstract 12592: Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry (2010) (0)
Abstract 15468: Association Between Natriuretic Peptides and Mortality Among Patients Admitted with Myocardial Infarction in the ACTION Registry-GWTG (2010) (0)
Lorcaserin Safety in Overweight or Obese Patients. (2019) (0)
ATOPAXAR AND ITS EFFECTS ON MARKERS OF PLATELET ACTIVATION AND INFLAMMATION: RESULTS FROM THE LANCELOT PROGRAM (2012) (0)
Author Disclosure Table (2008) (0)
Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes (2020) (0)
Emergency Department Administration of Thienopyridines in NSTEMI: Results from the ACTION Registry®-GWTGTM Registry (2014) (0)
High-dose statins in acute coronary syndromes [1] (multiple letters) (2005) (0)
Sex Differences in the Effectiveness of Early Coronary CT Angiography Compared to Standard Emergency Department Evaluation for Acute Chest Pain: The ROMICAT II Trial (2013) (0)
Myocardial Infarction and Evolocumab-Reply. (2021) (0)
and Injury : A Report From the National Cardiovascular Data Registry Short-Term Outcomes of Acute Myocardial Infarction in Patients With Acute Kidney (2012) (0)
Abstract 12497: Timing of ST Elevation MI is Related to Patient Baseline Characteristics (2010) (0)
Abstract 16014: Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51 (2012) (0)
Response to Letter Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarc (2009) (0)
Clinical study of Repatha: it does not affect patients’ cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis (2022) (0)
Abstract 14769: Outcomes of a Smartphone-based Application With Live Health-coaching Post-percutaneous Coronary Intervention (2020) (0)
P5537Clinical outcomes, mortality, and causes of death in patients with NSTEMI according to heart failure at admission: insights from a large contemporary revascularization trial (2018) (0)
ntithrombotic Strategy in Non–ST-Segment levation Myocardial Infarction Patients ndergoing Percutaneous Coronary Intervention (0)
Risk profile of clinical trial participants--reply. (2015) (0)
THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY: A NATIONAL REGISTRY-QUALITY IMPROVEMENT INTEGRATED PROGRAM IN CHINA (2014) (0)
Abstract 10481: Predictors of Bleeding Events in Patients Treated With Prasugrel or Clopidogrel: Insights From the TRITON-TIMI 38 Trial (2010) (0)
Unstable Angina/Non-ST-Elevation Myocardial Infarction in the Elderly (2005) (0)
Abstract 15643: Is Bleeding Risk Augmented With Acute Therapies Across Increasing INR Levels Among NSTEMI Patients on Home Warfarin Therapy? (2010) (0)
Considerations Regarding Antiplatelet Therapy in the Elderly (2011) (0)
New Drugs and Technologies Prasugrel (2010) (0)
Chapter 9 – Non–ST-Segment Elevation Acute Coronary Syndromes (2013) (0)
Abstract 14628: Characteristics and In-hospital Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. (2010) (0)
Acute Coronary Syndromes: A Companion to Braunwald’s Heart Disease (2004) (0)
Size Fit All? Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One (2006) (0)
Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents : Primary Endpoint Results from the Dual Antiplatelet Therapy Study (2014) (0)
Prasugrel – a third-generation thienopyridine (2008) (0)
236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial (2019) (0)
Abstract 11302: Improved Risk Stratification in Patients with ST-Elevation Myocardial Infarction Treated with Fibrinolysis by Combining New Q-Waves on the Initial Electrocardiogram with ST-Segment Resolution -- Observations from the CLARITY-TIMI 28 Trial (2011) (0)
Abstract 3995: Comparison of the Effects of Prasugrel and High Dose Clopidogrel on In Vivo and In Vitro Platelet Activation: Results from PRINCIPLE-TIMI 44 (2008) (0)
Abstract 16185: Biomarker-based Heart Failure Risk Stratification in Patients With Atherosclerotic Cardiovascular Disease: Observations From HPS-3/TIMI-55-REVEAL (2020) (0)
303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial (2020) (0)
CLINICAL TRIAL PARTICIPATION AFTER ACUTE CORONARY SYNDROME AND ASSOCIATED OUTCOMES: INSIGHT FROM THE ACTION REGISTRY-GWTG (2012) (0)
1118-82 Distinct modes of cardiovascular death associated with impaired epicardial and myocardial perfusion following fibrinolysis for ST elevation myocardial infarction (2004) (0)
Female gender is the strongest predictor of major hemorrhage in trials of combination of fibrinolytic and glycoprotein IIb/IIIa inhibitors (2003) (0)
Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial (2019) (0)
410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus (2019) (0)
Abstract 16393: Causes and Timing of Death in Patients With NSTE ACS: An Analysis of the TIMI Trials (2011) (0)
Abstract 5577: Short-Term Outcomes of STEMI and NSTEMI in Patients with Chronic Kidney Disease: A Report from the National Cardiovascular Data ACTION Registry (2008) (0)
Abstract 12797: Characteristics and Outcomes of Emergency Department Patients Treated with Thienopyridines: Results from the NCDR(R) (2011) (0)
Abstract 3996: Intrinsic Platelet Variability in Response to ADP Before Exposure to Thienopyridines Contributes to the Variability in Residual Platelet Reactivity to ADP After Treatment with Clopidogrel or Prasugrel: Results from PRINCIPLE-TIMI 44 (2008) (0)
P Acute Myocardial Infarction he Role of Clopidogrel in Early nd Sustained Arterial Patency After Fibrinolysis or ST-Segment Elevation Myocardial Infarction he ECG CLARITY – TIMI 28 Study (2006) (0)
883-2 The association of race with angiographic and clinical outcomes following fibrinolytic administration (2004) (0)
Abstract 3806: Effect of Risk on the Benefit of Enoxaparin versus Unfractionated Heparin in Patients with ST-Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial (2006) (0)
Abstract 17886: Impact of a Very Early Invasive Strategy in High Risk NSTEMI: Analysis From the TAO (Treatment for Acute Coronary Syndromes With Otamixaban) Trial (2016) (0)
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial Coronary Heart Disease (2005) (0)
Abstract 4993: Time from Symptom Onset to Hospital Presentation in Women with Myocardial Infarction: A Temporal Analysis from the CRUSADE and NCDR ACTION Registry (2008) (0)
788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58 (2021) (0)
Early intensive simvastatin may reduce CVD morbidity and mortality (2004) (0)
P1694Sex is not an independent predictor of ischemic outcomes or bleeding in NSTEMI patients undergoing percutaneous coronary intervention. Insights from the TAO trial (2019) (0)
Thrombolysis in Myocardial − Outcomes by Optimizing Platelet Inhibition With Prasugrel Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Print (2008) (0)
myocardial infarction with subsequent mortality Association of creatinine and creatinine clearance on presentation in acute (2011) (0)
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". (2018) (0)
RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58 (2023) (0)
DUAL ANTIPLATELET THERAPY BEYOND ONE YEAR FOLLOWING CORONARY STENTING IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION: A DUAL ANTIPLATELET THERAPY STUDY ANALYSIS (2016) (0)
REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES (2023) (0)
Abstract 3204: Assessment of Adiponectin and the Risk of Recurrent Cardiovascular Events: Observations from the PROVE IT-TIMI 22 Trial (2008) (0)
High-Dose Statins in Acute Coronary Syndromes—Reply (2005) (0)
Advantage of Prasugrel over Clopidogrel Holds across Range of Patient- and Procedure-Related Factors (2008) (0)
Overweight Cardiovascular Disease in the Developing World and its Cost-Effective Management (0)
Coronary Heart Disease Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes (2011) (0)
Abstract 12577: The Efficacy and Safety of Third Generation P2Y12 Inhibitors in Women versus Men: A Sex-Specific Meta-Analysis (2015) (0)
Assessment and Initial Management of ST-Segment Elevation Myocardial Infarction (2010) (0)
Abstract P149: Self versus Emergency Medical Service Transport for Patients With ST-Elevation Myocardial Infarction: Findings From the National Cardiovascular Data Registry ACTION - Get With the Guidelines (2011) (0)
1021-101 Association of glomerular filtration rate on presentation with subsequent mortality in non-ST elevation acute coronary syndromes (2004) (0)
High-dose statins in acute coronary syndromes. Authors' replies (2005) (0)
Abstract 4588: Regional Safety and Efficacy of Prasugrel Compared to Clopidogrel: A TRITON - TIMI 38 Analysis (2008) (0)
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. (2023) (0)
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. (2022) (0)
A SMARTPHONE-BASED APPLICATION POST-PERCUTANEOUS CORONARY INTERVENTION TO MANAGE CARDIOVASCULAR DISEASE RISK (2020) (0)
Abstract 4610: Stent Thrombosis Exhibits a Diurnal Variation With a Higher Incidence of Morning Events (2009) (0)
Antiplatelet Therapy in Acute Coronary Syndrome (ACS) and PCI: Practical Strategies to Improve Outcomes (2010) (0)
169: NON-INVASIVE MEASURE OF MUSCLE PH CORRELATES WITH SPLANCHNIC PERFUSION DURING SHOCK (2014) (0)
Abstract 2263: F1.2 Correlates with Ischemia by Holter Monitoring and is Suppressed by rNAPc2: an ANTHEM - TIMI 32 Biomarker Analysis (2006) (0)
Abstract 3487: Enoxaparin Reduces Recurrent MI and Death in Patients with STEMI Undergoing Fibrinolysis who Achieve Early ST Resolution: The ExTRACT-TIMI 25 ECG Study (2006) (0)
Abstract 17544: Utilization of Intensive Lipid-Lowering Therapy After an Acute Coronary Syndrome: Insights From the Triton-TIMI 38 Trial (2013) (0)
Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel (2016) (0)
Abstract P117: Longer Hospital Length of Stay in Non-ST-Elevation Myocardial Infarction Associated With Higher Risk but Less Evidenced-Based Treatment: Results From ACTION Registry (2011) (0)
INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY (2019) (0)
INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY (2019) (0)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 (2022) (0)
Use of a sonospectrographic digital electronic stethoscope to evaluate changes in acoustic signature of coronary flow before and after percutaneous coronary intervention (PCI) (2002) (0)
Title : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (0)
PATTERNS OF EARLY THIENOPYRIDINE USE AMONG CONTEMPORARY STEMI AND NSTEMI PATIENTS IN THE US: INSIGHTS FROM ACTION REGISTRY-GET WITH THE GUIDELINES (2012) (0)
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials (2022) (0)
Abstract 13389: High-Sensitivity Cardiac Troponin at Any Detectable Concentration Identifies Higher Risk of Major Cardiovascular Events in Patients With Stable Ischemic Heart Disease (2018) (0)
Coronary Heart Disease Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease (2010) (0)
Abstract 5594: The Impact of Prior Stroke on the Use of Evidence-based Therapies, and In-Hospital Outcomes in MI Patients: A Report of the NCDR ACTION GWTG Registry (2008) (0)
PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK (2019) (0)
Abstract 19423: Prevalence, Characteristics, Treatment and In-hospital Outcomes of Diabetes Mellitus in Patients with Acute Myocardial Infarction in China from the China Acute Myocardial Infarction Registry (2014) (0)
Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial (2020) (0)
Abstract 20496: Time Dependence of Association of Bleeding Events With Mortality in Patients Treated With Prasugrel or Clopidogrel: Insights From the TRITON-TIMI 38 Trial (2010) (0)
Antiplatelet agents make a comeback in ST-elevation myocardial infarction. (2007) (0)
APPLICATION OF THE TIMI RISK SCORE, A SIMPLE BEDSIDE TOOL, FOR TIMING OF DISCHARGE AFTER FIBRINOLYSIS OR PRIMARY ANGIOPLASTY FOR ST-ELEVATION MI IN THE EXTRACT-TIMI 25 AND TRITON-TIMI 38 TRIALS (2010) (0)
Reductions in VLDL and remnant cholesterol through inhibition of ANGPTL3 protein synthesis: An analysis from TRANSLATE-TIMI 70 (2022) (0)
FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58 (2022) (0)
Efficacy and safety of dapagliflozin according to baseline blood pressure – observations from DECLARE-TIMI 58 Trlial (2020) (0)
Abstract 5338: Universal Definition of Myocardial Infarction Classification and the Risk of Cardiovascular Death: Observations From the TRITON-TIMI 38 Trial (2009) (0)
Abstract 16182: Diabetics With Acute Chest Pain Have Similar Length of ED Stay From Early CCTA Compared to Standard Evaluation but More Downstream Testing and Radiation Exposure: The ROMICAT II Trial (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stephen D. Wiviott?

Stephen D. Wiviott is affiliated with the following schools: